Cargando…

Biomarkers to predict prognosis and response to checkpoint inhibitors

Nivolumab is a fully human immunoglobulin (Ig) G4 antibody that selectively inhibits the programmed death 1 (PD-1) immune checkpoint molecule, and has recently been launched for the treatment of renal cell cancer (RCC) in Japan. Based on its promising anti-tumor efficacy and manageable safety profil...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yuasa, Takeshi, Masuda, Hitoshi, Yamamoto, Shinya, Numao, Noboru, Yonese, Junji
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Japan 2017
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5533827/ https://www.ncbi.nlm.nih.gov/pubmed/28382562 http://dx.doi.org/10.1007/s10147-017-1122-1

Ejemplares similares

Pembrolizumab for a patient with metastatic castration‐resistant prostate cancer with microsatellite instability‐high
por: Fujiwara, Motohiro, et al.
Publicado: (2020)

Effectiveness and safety profile of pembrolizumab for metastatic urothelial cancer: A retrospective single‐center analysis in Japan
por: Fujiwara, Motohiro, et al.
Publicado: (2021)

Long-term complete response of antiandrogen withdrawal syndrome in a patient with metastatic prostate cancer: A case report
por: Sano, Masayuki, et al.
Publicado: (2016)

Unusual metastasis from renal cell cancer after partial nephrectomy and sequential targeted therapy
por: Yasuoka, Shotaro, et al.
Publicado: (2021)

The utility of diffusion‐weighted whole‐body imaging with background body signal suppression in detecting metastatic lesion of germ cell carcinoma
por: Yoshitomi, Kasumi Kaneko, et al.
Publicado: (2021)

Denosumab: a new option in the treatment of bone metastases from urological cancers
por: Yuasa, Takeshi, et al.
Publicado: (2012)

Improvement of renal function by changing the bone-modifying agent from zoledronic acid to denosumab
por: Yamasaki, Mutsushi, et al.
Publicado: (2016)

A case of gastric metastasis from renal cell cancer during the sequential targeted therapy
por: Uehara, Sho, et al.
Publicado: (2017)

Prior administration of a non-steroidal anti-androgen failed to prevent the flare-up caused by a luteinizing hormone-releasing hormone agonist in a patient with metastatic prostate cancer
por: Uehara, Sho, et al.
Publicado: (2015)

Clinical outcome of patients with pancreatic metastases from renal cell cancer
por: Yuasa, Takeshi, et al.
Publicado: (2015)

A risk stratification model based on four novel biomarkers predicts prognosis for patients with renal cell carcinoma
por: Kubota, Shigehisa, et al.
Publicado: (2020)

Recent advances in medical therapy for metastatic urothelial cancer
por: Yuasa, Takeshi, et al.
Publicado: (2018)

External validation of the Briganti 2019 nomogram to identify candidates for extended pelvic lymph node dissection among patients with high-risk clinically localized prostate cancer
por: Fukagawa, Eri, et al.
Publicado: (2021)

Relationship of B7-H3 expression in tumor cells and tumor vasculature with FOXP3+ regulatory T cells in renal cell carcinoma
por: Inamura, Kentaro, et al.
Publicado: (2019)

Potential non-invasive biomarkers in tumor immune checkpoint inhibitor therapy: response and prognosis prediction
por: Song, Ruixia, et al.
Publicado: (2023)

Therapeutic inhibition of mitochondrial function induces cell death in starvation-resistant renal cell carcinomas
por: Isono, Takahiro, et al.
Publicado: (2016)

Impact of radiotherapy to the primary tumor on the efficacy of pembrolizumab for patients with advanced urothelial cancer: A preliminary study
por: Fukushima, Hiroshi, et al.
Publicado: (2020)

Comparison Between Dose-Escalated Intensity Modulated Radiation Therapy and 3-Dimensional Conformal Radiation Therapy for Salvage Radiation Therapy After Prostatectomy
por: Shimoyachi, Nana, et al.
Publicado: (2021)

Predictive biomarkers for immune checkpoint inhibitor response in urothelial cancer
por: Parent, Pauline, et al.
Publicado: (2023)

Case Report: A Case of Trimethoprim/Sulfamethoxazole-Triggered Hypotensive Shock: Cytokine Release Syndrome Related to Immune Checkpoint Inhibitors and Drug-Induced Hypersensitivity Syndrome
por: Urasaki, Tetsuya, et al.
Publicado: (2021)

Early onset recall pneumonitis during targeted therapy with sunitinib
por: Yuasa, Takeshi, et al.
Publicado: (2013)

Longitudinal change in health-related quality of life after intensity-modulated radiation monotherapy for clinically localized prostate cancer
por: Yamamoto, Shinya, et al.
Publicado: (2013)

Organ-specific and tumor-size-dependent responses to sunitinib in clear cell renal cell carcinoma
por: Tsuchiya, Norihiko, et al.
Publicado: (2014)

Biomarkers for predicting the efficacy of immune checkpoint inhibitors
por: Wang, Chengji, et al.
Publicado: (2022)

Current landscape and future directions of biomarkers for predicting responses to immune checkpoint inhibitors
por: Zhu, Yingming, et al.
Publicado: (2018)

Predictive Biomarkers for Immune-Checkpoint Inhibitor Treatment Response in Patients with Hepatocellular Carcinoma
por: Ji, Jun Ho, et al.
Publicado: (2023)

Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitors
por: Bai, Rilan, et al.
Publicado: (2020)

Diagnostic performance of a computer-assisted diagnosis system for bone scintigraphy of newly developed skeletal metastasis in prostate cancer patients: search for low-sensitivity subgroups
por: Koizumi, Mitsuru, et al.
Publicado: (2017)

Biomarkers for response to immune checkpoint inhibitors in gastrointestinal cancers
por: Li, Meng, et al.
Publicado: (2022)

Interpretable systems biomarkers predict response to immune-checkpoint inhibitors
por: Lapuente-Santana, Óscar, et al.
Publicado: (2021)

Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Current Strategies and Biomarkers Predicting Response and/or Resistance
por: Pelizzaro, Filippo, et al.
Publicado: (2023)

A radiological complete response to pembrolizumab in a patient with metastatic upper urinary tract urothelial cancer and Lynch syndrome
por: Oki, Ryosuke, et al.
Publicado: (2022)

Predictive Biomarkers for Checkpoint Inhibitor Immune-Related Adverse Events
por: Les, Iñigo, et al.
Publicado: (2023)

Eosinophil as a biomarker for diagnosis, prediction, and prognosis evaluation of severe checkpoint inhibitor pneumonitis
por: Li, Yanlin, et al.
Publicado: (2022)

Biomarkers of therapeutic response with immune checkpoint inhibitors
por: Bindal, Poorva, et al.
Publicado: (2021)

NSCLC Biomarkers to Predict Response to Immunotherapy with Checkpoint Inhibitors (ICI): From the Cells to In Vivo Images
por: Liberini, Virginia, et al.
Publicado: (2021)

Testicular seminoma with a progressing pulmonary nodule and mediastinal lymphadenopathy without retroperitoneal metastasis
por: Sano, Yuta, et al.
Publicado: (2020)

New biomarkers for checkpoint inhibitor therapy
por: Burdett, Nikki, et al.
Publicado: (2020)

An oxidative stress biomarkers predict prognosis in gastric cancer patients receiving immune checkpoint inhibitor
por: Deng, Guiming, et al.
Publicado: (2023)

Abundance of TRAIL attenuated by HIF2α and c-FLIP affects malignancy in renal cell carcinomas
por: Isono, Takahiro, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_i3benkh0kga7na88o98jqj982o